EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities



High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities



Drug and Alcohol Dependence 81(3): 259-265



Injection drug users (IDUs) acquire the majority of new hepatitis C virus (HCV) infections and frequently use alcohol. Alcohol abuse accelerates liver disease among HCV-infected persons, can reduce the effectiveness of treatment for HCV infection and may be a contraindication for HCV treatment. HCV seropositive, HIV-negative IDUs aged 18-35 years in Baltimore, New York City and Seattle who were enrolled in a behavioral risk-reduction intervention trial underwent computerized self-interviews to assess baseline alcohol use and dependence and medical history. We measured problem alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT) scale. Of 598 participants, 84% responded "false" to: "it is safe for a person with HCV to drink alcohol". Problem drinking, defined as score >= 8 on AUDIT, was identified in 37%. Correlates of scoring >= 8 on AUDIT included homelessness, male gender, primarily injecting speedballs, having injected with used needles, prior alcohol treatment and depression. Although most HCV scropositive IDUs in our sample appear informed about their increased risk of liver disease from alcohol, two-fifths screened positive for problem alcohol use. These findings underscore the importance of referring HCV-positive persons to effective alcohol treatment programs to reduce future liver damage and improve eligibility for and effectiveness of treatment of HCV. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

(PDF emailed within 0-6 h: $19.90)

Accession: 012148909

Download citation: RISBibTeXText

PMID: 16129567

DOI: 10.1016/j.drugalcdep.2005.07.005



Related references

Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica de Mexico 49(3): 165-172, 2007

Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age?. Journal of Infectious Diseases 184(5): 659-660, 2001

Is the prevalence of hepatitis C virus RNA in anti-HCV-positive injection drug users positively correlated with age?. Journal of Infectious Diseases 184(5): 659-660, 1 September, 2001

Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health 92(3): 385-387, 2002

Low uptake of hepatitis C testing and high prevalence of risk behavior among HIV-positive injection drug users in Bangkok, Thailand. Journal of Acquired Immune Deficiency Syndromes 56(5): E133-E135, 2011

High Prevalence of Hepatitis C virus Among Injection Drug Users in Zhenjiang, Jiangsu, China. Indian Journal of Virology 22(2): 77-83, 2011

The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida. Memorias do Instituto Oswaldo Cruz 99(8): 789-793, 2005

The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida. Memorias do Instituto Oswaldo Cruz 99(8): 789-793, 2004

High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. Journal of Acquired Immune Deficiency Syndromes 29(2): 191-196, 2002

Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Communicable Disease and Public Health 1(2): 95-97, 1998

Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clinical Infectious Diseases 46(11): 1761-1768, 2008

High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. Journal of Acquired Immune Deficiency Syndromes 49(3): 327-332, 2008

Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 97(10): 1277-1287, October, 2002

Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseases 201(3): 378-385, 2010